Prophylactic heparin in palliative care: …to a challenging ideaBMJ 2006; 332 doi: https://doi.org/10.1136/bmj.332.7543.729 (Published 23 March 2006) Cite this as: BMJ 2006;332:729
- John C Chambers, Macmillan consultant (firstname.lastname@example.org)
- Katharine House Hospice, Adderbury, Oxfordshire OX17 3NL
EDITOR—Twenty eight (100%) hospice inpatients at least five days into thromboprophylaxis with low molecular weight heparin found it acceptable.1 The potential for lengthened life appeared the main reason for wanting prophylaxis and none knew any common symptoms of venous thromboembolism. All had irreversible deteriorations in performance status, and, as cancer itself is a risk for venous thromboembolism, …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial